Diana Rapalo
Family · Bethesda, MDNPI 1730710609
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,015 of the $12,616 with a category attached, or 79.4%. 31 manufacturers reported payments, led by Medtronic at 25.6% of the total. 2025 is the largest year on record at $4,713, 7.4 times the $637 reported in 2021. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $44.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Insulet Corporation$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Cequr Corporation$853
- Corcept Therapeutics$590
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$1,59013%
- Travel & lodging$1,0128%
- Food & beverage$10,01579%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 28 | $3,224 |
| Insulet Corporation | 19 | $1,514 |
| Lilly USA, LLC | 56 | $1,398 |
| Novo Nordisk | 44 | $1,178 |
| Cequr Corporation | 3 | $853 |
| Corcept Therapeutics | 17 | $590 |
| Dexcom, Inc. | 6 | $438 |
| AstraZeneca(2 entities) | 13 | $436 |
| Madrigal Pharmaceuticals | 7 | $392 |
| Mannkind Corporation | 12 | $334 |
| Tandem Diabetes Care, Inc. | 4 | $325 |
| Boehringer Ingelheim | 14 | $292 |
| Sanofi-aventis U.S. LLC | 7 | $276 |
| BETA Bionics, Inc. | 4 | $204 |
| Xeris Pharmaceuticals, Inc. | 7 | $141 |
| Amarin Pharma, Inc. | 2 | $136 |
| Amneal Pharmaceuticals LLC | 6 | $132 |
| AbbVie | 5 | $121 |
| Recordati_rare_diseases_inc. | 6 | $120 |
| Amgen | 6 | $104 |
| Radius Health, Inc. | 4 | $89 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Amphastar Pharmaceuticals, Inc. | 2 | $46 |
| Embecta Corp. | 1 | $43 |
| Antares Pharma, Inc. | 1 | $32 |
| Biomarin Pharmaceutical Inc. | 1 | $28 |
| Tolmar, Inc. | 2 | $26 |
| Zealand Pharma US, Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$2,735
- Omnipod$1,179
- CeQur Simplicity$853
- iLet Bionic Pancreas$357
- REZDIFFRA$243
- t:slim X2 Insulin Pump with Control-IQ$240
- FARXIGA$226
- Korlym$222
- DEXCOM G7 GSS (161)$145
- DEXCOM G6 TRANSMITTER$140
- RYBELSUS$125
- Wegovy$122
- iLet Insulin Infusion Kit Inset$119
- iLet Insulin Infusion Kit Contact Detach$119
- Vascepa$117
How this compares
$12,616 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 108 | $203,508 |
| JardianceEmpagliflozin | 100 | $146,135 |
| OzempicSemaglutide | 43 | $101,930 |
| TrulicityDulaglutide | 35 | $59,444 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $26,450 |
| FarxigaDapagliflozin Propanediol | 14 | $22,165 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $21,092 |
| JanuviaSitagliptin Phosphate | 14 | $17,000 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 22 | $1,593 |
| Ezetimibe | 35 | $383 |
| Atorvastatin Calcium | 48 | $318 |
| Metformin Hcl | 61 | $308 |
| Rosuvastatin Calcium | 16 | $249 |
| Gabapentin | 13 | $184 |
| Lisinopril | 25 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,398 | $262,952143 claims |
| Boehringer IngelheimJardiance | $292 | $146,135100 claims |
| Novo NordiskOzempic | $1,178 | $101,93043 claims |
| AstraZenecaFarxiga | $436 | $22,16514 claims |
| MerckJanuvia | $15 | $17,00014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Bethesda
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.